The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Original Article
Efficacy of Prophylactic Policy–Driven Tranexamic Acid Administration during Cesarean Delivery in a Rural Healthcare Setting
Abstract
Objectives: Postpartum hemorrhage (PPH) is a major contributor to maternal mortality worldwide and is a leading cause of pregnancy-related mortality in the United States. The American College of Obstetricians and Gynecologists, the Royal College of Obstetricians and Gynecologists, and the World Health Organization advocate for the early use of tranexamic acid (TXA) in the prevention of PPH. The purpose of this study was to determine the efficacy and patient characteristics of the use of prophylactic TXA administration during cesarean delivery (CD) as part of a newly instituted policy to reduce blood loss and PPH rates in a tertiary care regional rural and underserved maternal care center.Methods: An electronic quality assurance chart review from February 2020 through October 2021 of more than 2705 patients was conducted, comparing two groups after implementation of a TXA protocol for all CDs. In total, four CD groups were analyzed (control group without TXA before policy, PPH group without TXA before policy, TXA control group after policy, and PPH group with TXA after policy).
Results: PPH rates decreased with TXA use (9.7% vs 1.5%). TXA use was more likely to be given to patients with one or more of the following characteristics: commercial insurance, self-identified Asian race, admission from a doctor’s office, urgent CD delivery, fetal distress, abruptio placenta/placenta previa, and extended hospital length of stay with increased hospitalization cost. Subset analysis of 720 patients revealed decreased blood loss (896.4 ± 521.0 mL vs 771.1 ± 405.6 mL, P = 0.0004) and fewer blood transfusions with TXA use (6.7% vs 1.1%, P = 0.0001).
Conclusions: Prophylactic policy–driven TXA administration during CD protocol–driven TXA administration decreases PPH.
Posted in: Pregnancy37
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Division of Healthcare Improvement, The Joint Commission. Quick safety issue 51: proactive prevention of maternal death from maternal hemorrhage. https://www.jointcommission.org/resources/news-and-multimedia/newsletters/newsletters/quick-safety/quick-safety-issue-51-proactive-prevention-of-maternal-death-from-maternal-hemorrhage. Published October 29, 2019. Accessed July 26, 2024.
2. Centers for Disease Control and Prevention. Pregnancy-related deaths: data from maternal mortality review committees in 36 US states, 2017–2019. https://www.cdc.gov/maternal-mortality/php/data-research/mmrc-2017-2019.html. Published May 28, 2024. Accessed July 26, 2024.
3. World Health Organization. Postpartum haemorrhage. https://www.who.int/teams/sexual-and-reproductive-health-and-research-(srh)/areas-of-work/maternal-and-perinatal-health/postpartum-haemorrhage. Accessed July 26, 2024.
4. Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994-2006. Am J Obstet Gynecol. 2010;202:353.e1–e6.
5. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389: 2105–2116.
6. Lakshmi SD. Role of prophylactic tranexamic acid in reducing blood loss during elective caesarean section: a randomized controlled study. J Clin Diagn Res 2016;10:QC17–QC21.
7. Committee on Practice Bulletins-Obstetrics. Practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol 2017;130:e168–e186.
8. Roberts I, Perel P, Prieto-Merino D, et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ 2012;345:e5839.
9. Escobar MF, Nassar AH, Theron G, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynaecol Obstet 2022;157(Suppl 1):3–50.
10. Brenner A, Ker K, Shakur-Still H, et al. Tranexamic acid for post-partum haemorrhage: what, who and when. Best Pract Res Clin Obstet Gynaecol 2019;61:66–74.
11. Binyamin Y, Frenkel A, Gruzman I, et al. Prophylactic administration of tranexamic acid reduces blood products’ transfusion and intensive care admission in women undergoing high-risk cesarean sections. J Clin Med 2023;12:5253.
12. Hemapriya L, More G, Kumar A. Efficacy of tranexamic acid in reducing blood loss in lower segment cesearean section: a randomised controlled study. J Obstet Gyn India 2020;70: 479–484.
13. Lee SH, Kwek ME, Tagore S, et al. Tranexamic acid, as an adjunct to oxytocin prophylaxis, in the prevention of postpartum haemorrhage in women undergoing elective caesarean section: a single-centre double-blind randomised controlled trial. BJOG 2023;130:1007–1015.
14. Pacheco LD, Clifton RG, Saade GR, et al. Tranexamic acid to prevent obstetrical hemorrhage after cesarean delivery. N Engl J Med 2023;388:1365–1375.
15. Centers for Disease Control and Prevention. Pregnancy mortality surveillance system. https://www.cdc.gov/maternal-mortality/php/pregnancy-mortality-surveillance/index.html. Accessed July 26, 2024.
16. Lisonkova S, Haslam MD, Dahlgren L, et al. Maternal morbidity and perinatal outcomes among women in rural versus urban areas. CMAJ 2016;188:E456–E465.
17. Roberts I, Brenner A, Shakur-Still H. Tranexamic acid for bleeding: much more than a treatment for postpartum hemorrhage. Am J Obstet Gynecol MFM 2023;5(Suppl 2):100722.
18. Li C, Gong Y, Dong L, et al. Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage prevention? A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e5653.
19. Miller S, Lester F, Hensleigh P. Prevention and treatment of postpartum hemorrhage: new advances for low-resource settings. J Midwifery Womens Health 2004;49:283–292.
20. Xu J, Gao W, Ju Y. Tranexamic acid for the prevention of postpartum hemorrhage after cesarean section: a double-blind randomization trial. Arch Gynecol Obstet 2013;287:463–468.
21. Simonazzi G, Bisulli M, Saccone G, et al. Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand 2016;95:28–37.
22. Ahmadzia HK, Phillips JM, Katler QS, et al. Tranexamic acid for prevention and treatment of postpartum hemorrhage: an update on management and clinical outcomes. Obstet Gynecol Surv 2018;73:587–594.
23. Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013;209:449.e1–449.e7.
24. Wang HY, Hong SK, Duan Y, et al. Tranexamic acid and blood loss during and after cesarean section: a meta-analysis. J Perinatol 2015;35:818–825.
25. Dazelle WDH, Ebner MK, Kazma J, et al. Tranexamic acid for the prevention of postpartum hemorrhage: a cost-effectiveness analysis. J Thromb Thrombolysis 2023;56:128–136.
26. Howard DC, Jones AE, Skeith A, et al. Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. Am J Obstet Gynecol MFM 2022;4:100588.
x 27. Sudhof LS, Shainker SA, Einerson BD. Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis. Am J Obstet Gynecol 2019;221:275.e1–275.e12.
